natgillin/translations-raw huggingface dataset:
Pregnant and breast-feeding women should not have any contact with the product and should avoid operating rooms and animal recovery areas.
Nosečnice in doječe matere ne smejo priti v stik z zdravilom in se morajo izogibati operacijskim sobam in prostorom za prebujanje živali.
Pregnant and lactating women
Noseče in doječe ženske.
Pregnant mice exposed to axitinib showed an increased occurrence of cleft palate malformations and skeletal variations, including delayed ossification, at exposure levels below the expected human exposure.
Pri brejih miših, izpostavljenih aksitinibu, so ugotavljali povečano pogostnost pojavljanja razcepljenega neba in sprememb na skeletu, vključno z zapoznelo zakostenitvijo, pri stopnjah izpostavljenosti, ki so bile manjše od pričakovane izpostavljenosti pri ljudeh.
Pregnant or breast-feeding mothers must not take PREZISTA unless specifically directed by the doctor.
Med nosečnostjo in dojenjem ne smete jemati zdravila PREZISTA, razen če vam jemanje izrecno naroči vaš zdravnik.
Pregnant or breast-feeding mothers should not take Kaletra oral solution unless specifically directed by the doctor.
Nosečnice ali doječe matere ne smejo jemati zdravila Kaletra peroralna raztopina, razen če jim tega posebej ne naroči zdravnik.
pregnant or breast-feeding women;
noseče ali doječe ženske;
pregnant or breastfeeding women;
nosečnicah ali ženskah, ki dojijo;
Pregnant rabbits treated orally with 7.5 mg/kg/day (7500 times the recommended ophthalmic dose) caused increased post- implantation loss (see section 4.6).
Peroralni odmerek 7,5 mg/kg/dan (7500-kratnik priporočenega okularnega odmerka) je pri brejih samicah kuncev povzročil povečano izgubo po nidaciji (glejte poglavje 4.6).
Pregnant staff should be excluded from handling the medicinal product.
Nosečnice med osebjem morajo biti izključene iz rokovanja s tem zdravilom.
Pregnant staff should be excluded from working with this medicinal product.
Nosečnice ne smejo delati s tem zdravilom.
Pregnant staff should be excluded from working with this medicinal product.
Nosečnice ne smejo rokovati z zdravilom
Pregnant staff should be excluded from working with this medicinal product.
Nosečnice ne smejo rokovati z zdravilom.
Pregnant staff should be excluded from working with this medicine
Noseče zdravstvene delavke ne smejo delati s tem zdravilom
Pregnant staff should not handle Abraxane.
Noseče osebje ne sme rokovati z zdravilom Abraxane.
Pregnant staff should not handle ONIVYDE considering the cytotoxic nature of the medicinal product.
Nosečnice z zdravilom ONIVYDE zaradi njegove citotoksičnosti ne smejo delati.
Pregnant staff should not handle ONIVYDE.
Nosečnice z zdravilom ONIVYDE ne smejo delati.
Pregnant staff should not handle the cytotoxic preparation.
Noseče članice osebja ne smejo delati s citotoksičnimi zdravili.
Pregnant Women
Nosečnice
Pregnant women (see section 4.6)
nosečnice (glejte poglavje 4.6);
Pregnant women (see section 4.6).
Nosečnice (glejte poglavje 4.6).
Pregnant women (see sections 4.4, 4.6 and 5.3).
Noseče ženske (glejte poglavja 4.4, 4.6 in 5.3).
Pregnant women and women of child- bearing potential should not administer this product.
Noseče ženske in ženske, ki bi lahko zanosile, naj tega izdelka ne dajejo.
Pregnant women and women of child- bearing potential should not administer this product.
Noseče ženske in ženske, ki bi lahko zanosile, naj tega zdravila ne dajejo.
Pregnant women may receive oseltamivir, after considering the available safety information, the pathogenicity of the circulating influenza virus strain and the underlying condition of the pregnant woman.
Nosečnice lahko prejmejo zdravilo Ebilfumin upoštevajoč razpoložljive varnostne informacije, patogenost krožečega seva virusa gripe in osnovno zdravstveno stanje nosečnice.
Pregnant women may receive Tamiflu, after considering the available safety information, the pathogenicity of the circulating influenza virus strain and the underlying condition of the pregnant woman.
Nosečnice lahko prejmejo zdravilo Tamiflu, upoštevajoč razpoložljive varnostne informacije, patogenost krožečega seva virusa gripe in osnovno zdravstveno stanje nosečnice.
Pregnant women must avoid contact with cytostatic medicinal product.
Nosečnice se morajo izogibati stiku s citotoksičnimi učinkovinami.
Pregnant women must not take this medicine.
Nosečnice ne smejo jemati tega zdravila.
Pregnant women must take extra precautions when handling Panacur AquaSol as effects on the developing baby cannot be excluded.
Še zlasti previdno morajo z zdravilom Panacur AquaSol ravnati nosečnice, saj učinkov zdravila na nerojenega otroka ni mogoče izključiti.
Pregnant women should not administer the veterinary medicinal product.
Nosečnice zdravila ne smejo dajati.
Pregnant women should not be treated with Raptiva.
Nosečnic ne smemo zdraviti z Raptivo.
Pregnant women should not be vaccinated with ProQuad.
Nosečnic se ne sme cepiti s cepivom ProQuad.
Pregnant women should not take EDURANT unless specifically directed by the doctor.
Nosečnice ne smejo jemati zdravila EDURANT, razen če jim to posebej naroči zdravnik.
Pregnant women should take special care to avoid accidental oral exposure because ACE inhibitors have been found to affect the unborn child during pregnancy in humans.
Nosečnice naj pazijo, da ne pride do nenamerne peroralne izpostavljenosti, saj je bilo ugotovljeno, da zaviralci ACE vplivajo na nerojenega otroka med nosečnostjo pri ljudeh.
Pregnant women should take special care to avoid contact with the product because substances acting on the RAAS, such as Angiotensin Receptor Blockers (ARBs) and ACE inhibitors (ACEi), have been found to affect the unborn child during pregnancy in humans.
Nosečnice morajo biti posebno previdne, da preprečijo stik z zdravilom, saj so ugotovili, da pri ljudeh snovi, ki vplivajo na RAAS, kot so blokatorji angiotenzinskih receptorjev (ARB, angiotensin receptor blockers) in zaviralci ACE med nosečnostjo vplivajo na nerojenega otroka.
Pregnant women should take special care to avoid contact with the product because substances acting on the RAAS, such as Angiotensin Receptor Blockers (ARBs) and ACE inhibitors (ACEi), have been found to affect the unborn child during pregnancy in humans.
Nosečnice morajo biti posebno previdne, da preprečijo stik z zdravilom, saj so ugotovili, da pri ljudeh snovi, ki vplivajo na RAAS, kot so blokatorji angiotenzinskih receptorjev (ARB, angiotensin receptor blockers) in zaviralci ACE, med nosečnostjo vplivajo na nerojenega otroka.
Pregnant women should take special care to avoid contact with the product.
Nosečnice morajo biti še posebej previdne, da ne pridejo v stik z zdravilom.
Pregnant women who have either not had chickenpox or have not been vaccinated against chickenpox.
Nosečnicami, ki še niso imele noric ali niso bile cepljene proti noricam.
Pregnant women with mechanical prosthetic heart valves may be at higher risk for thromboembolism.
Pri nosečnicah z mehaničnimi umetnimi srčnimi zaklopkami je lahko povečano tveganje za trombembolijo.
pregnant women without documented positive history of varicella (chickenpox) or laboratory evidence of prior infection, newborn infants of mothers without documented positive history of varicella or laboratory evidence of prior infection.
nosečnice brez dokumentirane prejšnje okužbe z noricami (varičelo) ali laboratorijskega dokaza prebolele okužbe, novorojenčki mater brez dokumentirane prejšnje okužbe z noricami ali laboratorijskega dokaza prebolele okužbe.
Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with leflunomide and thereafter as long as the plasma levels of the active metabolite are above 0.02 mg/L (see section 4.6).
Nosečnice in ženske v rodni dobi, ki med zdravljenjem z leflunomidom ne uporabljajo zanesljive kontracepcije; to velja tudi po zdravljenju, vse dokler je plazemska koncentracija aktivnega presnovka nad 0,02 mg/l (glejte poglavje 4.6).
Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with leflunomide and thereafter as long as the plasma levels of the active metabolite are above 0.02 mg/L (see section 4.6).
Nosečnice in ženske v rodni dobi, ki med zdravljenjem z leflunomidom ne uporabljajo zanesljive kontracepcije; to velja tudi po zdravljenju, vse dokler je plazemska koncentracija aktivnega presnovka nad 0,02 mg/l (glejte tudi poglavje 4.6).
Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with leflunomide and thereafter as long as the plasma levels of the active metabolite are above 0.02 mg/l (see section 4.6).
Nosečnice in ženske v rodni dobi, ki med zdravljenjem z leflunomidom ne uporabljajo zanesljive kontracepcije; to velja tudi še po zdravljenju, vse dokler je plazemska koncentracija aktivnega presnovka nad 0,02 mg/l (glejte poglavje 4.6).
Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with leflunomide and thereafter as long as the plasma levels of the active metabolite are above 0.02 mg/L (see section 4.6).
Nosečnice in ženske v rodni dobi, ki med zdravljenjem z leflunomidom ne uporabljajo zanesljive kontracepcije; to velja tudi še po zdravljenju, vse dokler je plazemska koncentracija aktivnega presnovka nad 0,02 mg/l (glejte tudi poglavje 4.6).
Pregnant women:
Nosečnice:
Preliminary data from England and Wales reported less than 1 year following introduction of routine immunisation at 2, 4 and 13 months with a single dose catch-up programme for children 13 to 23 months of age have suggested that effectiveness of this schedule might be lower against serotype 6B than against the other serotypes in the vaccine.
Predhodni podatki iz Anglije in Walesa, o katerih so poročali manj kot 1 leto po uvedbi rutinskega cepljenja pri 2, 4 in 13 mesecih z naknadnim programom z enim samim odmerkom pri otrocih, starih 13 do 23 mesecev, so pokazali, da utegne biti učinkovitost te sheme manjša proti serotipu 6B kot proti drugim serotipom v cepivu.
Preliminary data in children below 12 are consistent with those obtained in adolescents up to 17 years of age.
Predhodni podatki pri otrocih, mlajših od 12 let, so skladni s podatki, pridobljenimi pri mladostnikih do 17. leta starosti.
Preliminary results from a clinical study including a limited number of volunteers showed no interaction with the antibody response to Dukoral when a live oral vaccine (enterocapsules) against typhoid was given simultaneously with Dukoral.
Preliminarni rezultati klinične raziskave, v kateri je sodelovalo omejeno število prostovoljcev, niso pokazali interakcij v odzivu protiteles na Dukoral pri sočasni uporabi živega peroralnega cepiva (enterokapsul) proti tifusu in Dukorala.
Preliminary results from a supportive study (Study ELT116826), an ongoing non-randomised, phase II, single-arm, open-label study in refractory SAA subjects, showed consistent results.
Preliminarni rezultati potekajoče podporne študije (študija ELT116826), ki je nerandomizirana odprta študija faze II z eno skupino bolnikov z neodzivno hudo aplastično anemijo, so skladni z navedenimi.
Premature discontinuation of filgrastim therapy, prior to the time of the expected neutrophil nadir, is not recommended.
Tudi prezgodnja prekinitev zdravljenja z nivestimom, pred pojavom pričakovanega najmanjšega števila nevtrofilcev, ni priporočljiva.
Premature discontinuation of Grastofil therapy, prior to the time of the expected neutrophil nadir, is not recommended.
Prezgodnja prekinitev zdravljenja z Grastofilom , preden število nevtrofilcev pade na pričakovano najnižjo raven, ni priporočljiva.
Premature discontinuation with any antiplatelet therapy, including Brilique, could result in an increased risk of cardiovascular (CV) death or MI due to the patient’s underlying disease.
Prezgodnje prenehanje uporabe kateregakoli antiagregacijskega zdravila, tudi zdravila Brilique, lahko poveča tveganje kardiovaskularne smrti ali miokardnega infarkta zaradi njihove osnovne bolezni.
premature ejaculation
prezgodnja ejakulacija
Premature fusion of the epiphyses has been reported in patients exposed to Erivedge.
Pri bolnikih, izpostavljenih zdravilu Erivedge, so poročali o prezgodnjem zraščanju epifiz.
Premature infants
Nedonošenčki
Premature Infants
Prezgodaj rojeni dojenčki
Premature infants who have already been transfused by the start of treatment with NeoRecormon are not likely to benefit as much as untransfused infants.
Pri nedonošenčkih, ki so pred zdravljenjem z zdravilom NeoRecormon že dobili transfuzijo, je pričakovana koristnost zdravljenja manjša kot pri tistih, ki transfuzije niso dobili.
Premature infants, for whom the corrected age of 5 weeks has not been reached (the corrected age being calculated by subtracting the number of weeks of prematurity from the actual age)
Prezgodaj rojeni dojenčki, ki še niso dosegli popravljene starosti 5 tednov (popravljena starost se izračuna tako, da odštejemo število tednov prezgodnjega rojstva od dejanske starosti)
Premature menopause Ovarian failure**
predčasna menopavza odpoved jajčnikov
Premature ovarian failure confirmed by a specialist gynaecologist
prezgodnja odpoved jajčnikov, ki jo potrdi specialist ginekolog,
Premature ovarian failure confirmed by a specialist gynaecologist
prezgodnja odpoved jajčnikov, ki jo potrdi specialist ginekolog;
Premature ovarian failure confirmed by a specialist gynaecologist.
Prezgodnja odpoved jajčnikov, ki jo potrdi specialist ginekolog.
Premature rupture of the membranes >30 weeks of gestation
prezgoden razpok plodnega mehurja > 30 tednov gestacije,
Premedication and additional medication recommendations
Priporočila za premedikacijo in dodatna zdravila
Premedication consisting of an analgesic/anti-pyretic drug and an anti-histaminic drug, should always be administered before each infusion of MabThera.
Pred vsako infuzijo zdravila MabThera je treba dati premedikacijo, ki vključuje analgetike/antipiretike in antihistaminike.
Premedication for prevention of infusion reaction
Premedikacija za preprečevanje infuzijske reakcije
Premedication in dogs and cats before induction and maintenance of general anaesthesia.
Premedikacija pri psih in mačkah pred uvajanjem in vzdrževanjem splošne anestezije.
Premedication in dogs and cats before induction and maintenance of general anaesthesia.
Priprava na operacije pri psih in mačkah pred uvajanjem in vzdrževanjem splošne anestezije.
Premedication should only be carried out in combination with butorphanol-analgesia.
Premedikacija se lahko izvaja le v kombinaciji z analgezijo z butorfanolom.
Premedication to reduce the risk of infusion related reactions is outlined in Table 1 and 2 (see also section 4.4).
Premedikacija za zmanjšanje tveganja za reakcije, povezane z infuzijo, je prikazana v preglednicah 1 in 2 (glejte tudi poglavje 4.4).
Premedication to reduce the risk of infusion related reactions is outlined in Table 1 and 2.
Premedikacija za zmanjšanje tveganja za reakcije, povezane z infuzijo, je prikazana v preglednicah 1 in 2.
Premedication with an H1 antagonist (e.g., diphenhydramine) and dexamethasone (or equivalent medicinal products) should be given, intravenously, 30–60 minutes prior to the olaratumab doses on days 1 and 8 of cycle 1 in all patients.
Potrebna je intravenska premedikacija z antagonistom H1 (npr. difenhidraminom) in deksametazonom (ali ekvivalentnimi zdravili) od 30 do 60 minut pred odmerkom olaratumaba, 1. in 8. dan prvega cikla pri vseh bolnikih.
Premedication with antihistamines and/or glucocorticoids may be considered.
Treba je pretehtati možnost priprave z uporabo antihistaminikov in/ali glukokortikoidov.
Premedication with antipyretic and antihistamine may be considered.
Morda bo potrebna premedikacija z antipiretikom in antihistaminikom.
Premedication with dexmedetomidine will significantly reduce the dosage of the induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia.
Premedikacija z deksmedetomidinom bistveno zmanjša odmerke sredstva za indukcijo in zmanjša odmerke hlapnega anestetika za vzdrževanje anestezije.
Premedication with dexmedetomidine will significantly reduce the dose of the induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia.
Premedikacijz deksmedetomidinom bistveno zmanjša odmerke sredstva za indukcijo in zmanjša odmerke hlapnega anestetika za vzdrževanje anestezije.
Premedication with glucocorticoids should be considered if MabThera is not given in combination with glucocorticoid-containing chemotherapy-.
Če zdravilo MabThera ni uporabljeno v kombinaciji s kemoterapijo, ki vključuje glukokortikoid, je treba razmisliti o premedikaciji z glukokortikoidi.
Premedication, general health, and pregnancy and contraception checks immediately before treatment
pregledi glede premedikacije, splošnega zdravja ter nosečnosti in kontracepcije tik pred zdravljenjem;
Premenopausal women
Ženske pred menopavzo
Premix for medicated feed
Predmešanica za medicirano krmo
Premix for medicated feeding stuff
Predmešanica za izdelavo medicinirane krme
Premix for medicated feeding stuff
Predmešanica za pripravo zdravilne krmne mešanice.
Premix for medicated feeding stuff.
Predmešanica za zdravilno krmno mešanico
Premix for medicated feedingstuff
Predmešanica za pripravo zdravilne krmne mešanice.
Premix solution: Chemical and physical in-use stability has been demonstrated for 8 hours when stored either between 2°C and 8°C or at room temperature (below 25°C).
Osnovna raztopina: dokazano je, da je osnovna raztopina kemijsko in fizikalno stabilna 8 ur, če je shranjena pri temperaturi med 2 in 8°C ali pri sobni temperaturi (do 25°C).
Premix solution: The premix solution contains 10 mg/ml docetaxel and should be used immediately after preparation.
Osnovna raztopina: Osnovna raztopina vsebuje 10 mg docetaksela/ml in jo je treba uporabiti takoj po pripravi.
Prenatal exposure of rat pups to phenylacetate (the active metabolite of phenylbutyrate) produced lesions in cortical pyramidal cells; dendritic spines were longer and thinner than normal and reduced in number.
Izpostavitev podganjih mladičev fenilacetatu (aktivnemu presnovku fenilbutirata) pred rojstvom je proizvedla lezije v piramidnih kortikalnih celicah, dendriti pa so bili daljši in tanjši kot običajno, ter prisotni v manjšem številu.
Prenatal exposure of rat pups to phenylacetate (the active metabolite of phenylbutyrate) produced lesions in cortical pyramidal cells; dendritic spines were longer and thinner than normal and reduced in number.
Pri izpostavitvi podganjih mladičev fenilacetatu (aktivnemu presnovku fenilbutirata) pred rojstvom je prišlo do lezij v piramidnih kortikalnih celicah, dendriti pa so bili daljši in tanjši kot običajno ter prisotni v manjšem številu.
prenorphi ne
(1,78-2,40)
prenorphine
(1,78-2,68)
Preotact 100 micrograms powder and solvent for solution for injection in a pre-filled pen.
Preotact 100 mikrogramov prašek in vehikel za raztopino za injiciranje v napolnjenem injekcijskem peresniku
Preotact 100 micrograms powder and solvent for solution for injection Parathyroid hormone
Preotact 100 mikrogramov prašek in vehikel za raztopino za injiciranje
Preotact can be used for up to 24 months, after which patients can be treated with a bisphosphonate (a medicine that reduces bone loss).
Zdravilo Preotact se lahko uporablja največ 24 mesecev, zatem pa se bolnice lahko začne zdraviti z difosfonatom (zdravilom za zmanjšanje izgube kostne mase).
Preotact has been administered in single doses up to 5 micrograms/kg and in repeated doses of up to 3 microgramskgday for 3 days and up to 2.5 microgramskgday for 7 days.
Zdravilo Preotact je bilo uporabljeno v posameznih odmerkih do 5 g/kg ter v ponavljajočih se odmerkih do 3 g/kg/dan za 3 dni in do 2,5 g/kg/dan za 7 dni.
Preotact is available in a pack with 2 pre-filled pens.
Zdravilo je na voljo v pakiranju z 2 napolnjenima injekcijskima peresnikoma.
Preotact is available in packs of 2 pre-filled pens.
Zdravilo je na voljo v pakiranju, ki vsebuje 2 napolnjena injekcijska peresnika.
Preotact is contraindicated in patients
Zdravilo Preotact je kontraindicirano pri bolnicah
Preotact is indicated for the treatment of osteoporosis in postmenopausal women at high risk of fractures (see section 5.1).
povečano tveganje za zlome (glejte poglavje 5.1).
Preotact is injected using a pre-filled pen.
Zdravilo Preotact se injicira z napolnjenim injekcijskim peresnikom.
Preotact is supplied in a pre-filled pen containing a cartridge.
Zdravilo Preotact je na voljo v napolnjenem injekcijskem peresniku z enim vložkom.
Preotact should therefore not be used in patients with severe hepatic impairment (see section 4.3).
Zato zdravila Preotact ne smemo uporabljati pri bolnicah s hudo okvaro jeter (glejte poglavje 4.3).
PrEP reminder card for the individual at risk (to be provided by HCP):
Izobraževalno gradivo PrEP za ogrožene posameznike (ki jo priskrbi zdravstveni delavec):
Prepandemic influenza vaccine (H5N1) (split virion, inactivared, adjuvanted)
Prepandrix prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom)
Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted)
Prepandemično cepivo proti gripi (H5N1) (z delci virionov, inaktivirano, z adjuvansom)
Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals is a ‘prepandemic’ vaccine.
Cepivo proti gripi (H5N1) (z delci virusa, inaktivirano, z adjuvansom) GlaxoSmithKline Biologicals je „prepandemično“ cepivo.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a suspension for injection in a pre-filled syringe.
Cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics je suspenzija za injiciranje v napolnjeni injekcijski brizgi.
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a vaccine for use in adults (from 18 to 60 years old). and elderly (over 60 years old).
Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics je cepivo, ki se uporablja pri odraslih (starih med 18 do 60 let) in starejših osebah (starih nad 60 let).
Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics is a ‘prepandemic’ vaccine.
Zdravilo Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics je „prepandemsko“ cepivo.
Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics prepandemsko cepivo proti gripi (H5N1) (s površinskim antigenom, inaktivirano, z adjuvansom)
Prepandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture)
Cepivo proti prepandemski gripi (H5N1) (s celimi virioni, inaktivirano, pripravljeno v celični kulturi)
Prepandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture)
Predpandemsko cepivo proti gripi (H5N1) (s celimi virioni, inaktivirano, pripravljeno v celični kulturi)
Prepandrix consists of two containers: Suspension: multidose vial containing the antigen, Emulsion: multidose vial containing the adjuvant.
Cepivo Prepandrix je na voljo v dveh vsebnikih: suspenzija: večodmerna viala z antigenom, emulzija: večodmerna viala z adjuvansom.
Prepandrix contains a flu strain called ‘A/Indonesia/05/2005’ (H5N1).
Cepivo Prepandrix vsebuje sev gripe, imenovan „A/Indonesia/05/2005“ (H5N1).
Prepandrix is a vaccine for use in adults from 18 years old.
Cepivo Prepandrix uporabljamo pri odraslih, starejših od 18 let.
Prepandrix is a ‘prepandemic’ vaccine.
Zdravilo Prepandrix je „prepandemsko“ cepivo.
Preparation
Pripravljanje zdravila
Preparation - Reconstitution procedure
Priprava – postopek rekonstitucije
Preparation and administration of Levetiracetam Hospira concentrate
Priprava in uporaba koncentrata zdravila Levetiracetam Hospira